Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:12 AM
Ignite Modification Date:
2025-12-25 @ 2:12 AM
NCT ID:
NCT06541860
Eligibility Criteria:
Inclusion Criteria:
Phase I
* Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
* Patients aged ≥ 18 years
* Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Phase II
* Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
* Patients aged ≥ 18 years
* Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Exclusion Criteria:
* Patients not willing to consent to review of clinical data
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06541860
Study Brief:
Protocol Section:
NCT06541860